-
Je něco špatně v tomto záznamu ?
Carbonyl reduction of warfarin: Identification and characterization of human warfarin reductases
P. Malátková, S. Sokolová, L. Chocholoušová Havlíková, V. Wsól,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
- MeSH
- 3-hydroxysteroid dehydrogenasy metabolismus MeSH
- aldehydreduktasa metabolismus MeSH
- alkoholoxidoreduktasy metabolismus MeSH
- antikoagulancia metabolismus MeSH
- biotransformace MeSH
- Escherichia coli genetika metabolismus MeSH
- exprese genu MeSH
- hydroxyprostaglandindehydrogenasy metabolismus MeSH
- izoenzymy metabolismus MeSH
- jaterní mikrozomy enzymologie MeSH
- játra enzymologie MeSH
- kinetika MeSH
- kultivační média chemie MeSH
- lidé MeSH
- oxidace-redukce MeSH
- rekombinantní proteiny metabolismus MeSH
- stereoizomerie MeSH
- vysokoúčinná kapalinová chromatografie MeSH
- warfarin metabolismus MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Warfarin is a widely used anticoagulant and, unfortunately, is a drug that is commonly implicated in serious adverse events including fatalities. Although several factors, including the metabolism of warfarin via CYP450, have been reported to affect the safety and efficacy of warfarin therapy, the wide variance in the warfarin dosage in patients has not been completely clarified. In addition to the oxidative metabolism of warfarin mediated by CYP450, reductive metabolism is involved in warfarin biotransformation. However, the reductive metabolism of warfarin has been largely unexplored and deserves further investigation. We studied warfarin reduction by human liver fractions and found a 9-fold higher velocity of warfarin reduction in the cytosol than in microsomes (Vmax=77.2 vs. 8.7pmol/mgprotein/min, respectively). Furthermore, of nine recombinant cytosolic carbonyl reducing enzymes tested for their ability to reduce warfarin, AKR1C3 and CBR1 were identified as warfarin reductases and their kinetic parameters were determined. The internal clearance of warfarin was 3 orders of magnitude higher with AKR1C3 than with CBR1 (CLint=65.922 vs. 0.070μl/mgprotein/min, respectively). This is the first time that warfarin reducing enzymes in human liver subcellular fraction have been identified. Moreover, we have described the chiral aspects of warfarin reduction using an HPLC method that enabled the detection of individual warfarin alcohol stereoisomers. Cytosol and AKR1C3 exhibit the stereoselective metabolism of (R)-warfarin to preferentially form (SR)-warfarin alcohol as the primary in vivo metabolite of warfarin. On the other hand, microsomes and CBR1 preferentially reduce (S)-warfarin to form (RS)-warfarin alcohol and (SS)-warfarin alcohol, respectively.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17024082
- 003
- CZ-PrNML
- 005
- 20170829110949.0
- 007
- ta
- 008
- 170720s2016 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.bcp.2016.03.025 $2 doi
- 035 __
- $a (PubMed)27055738
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Malátková, Petra $u Department of Biochemical Sciences, Faculty of Pharmacy, Charles University, Heyrovského 1203, CZ-50005 Hradec Králové, Czech Republic. Electronic address: Petra.Malatkova@faf.cuni.cz.
- 245 10
- $a Carbonyl reduction of warfarin: Identification and characterization of human warfarin reductases / $c P. Malátková, S. Sokolová, L. Chocholoušová Havlíková, V. Wsól,
- 520 9_
- $a Warfarin is a widely used anticoagulant and, unfortunately, is a drug that is commonly implicated in serious adverse events including fatalities. Although several factors, including the metabolism of warfarin via CYP450, have been reported to affect the safety and efficacy of warfarin therapy, the wide variance in the warfarin dosage in patients has not been completely clarified. In addition to the oxidative metabolism of warfarin mediated by CYP450, reductive metabolism is involved in warfarin biotransformation. However, the reductive metabolism of warfarin has been largely unexplored and deserves further investigation. We studied warfarin reduction by human liver fractions and found a 9-fold higher velocity of warfarin reduction in the cytosol than in microsomes (Vmax=77.2 vs. 8.7pmol/mgprotein/min, respectively). Furthermore, of nine recombinant cytosolic carbonyl reducing enzymes tested for their ability to reduce warfarin, AKR1C3 and CBR1 were identified as warfarin reductases and their kinetic parameters were determined. The internal clearance of warfarin was 3 orders of magnitude higher with AKR1C3 than with CBR1 (CLint=65.922 vs. 0.070μl/mgprotein/min, respectively). This is the first time that warfarin reducing enzymes in human liver subcellular fraction have been identified. Moreover, we have described the chiral aspects of warfarin reduction using an HPLC method that enabled the detection of individual warfarin alcohol stereoisomers. Cytosol and AKR1C3 exhibit the stereoselective metabolism of (R)-warfarin to preferentially form (SR)-warfarin alcohol as the primary in vivo metabolite of warfarin. On the other hand, microsomes and CBR1 preferentially reduce (S)-warfarin to form (RS)-warfarin alcohol and (SS)-warfarin alcohol, respectively.
- 650 _2
- $a 3-hydroxysteroid dehydrogenasy $x metabolismus $7 D015096
- 650 _2
- $a alkoholoxidoreduktasy $x metabolismus $7 D000429
- 650 _2
- $a aldehydreduktasa $x metabolismus $7 D000449
- 650 _2
- $a antikoagulancia $x metabolismus $7 D000925
- 650 _2
- $a biotransformace $7 D001711
- 650 _2
- $a vysokoúčinná kapalinová chromatografie $7 D002851
- 650 _2
- $a kultivační média $x chemie $7 D003470
- 650 _2
- $a Escherichia coli $x genetika $x metabolismus $7 D004926
- 650 _2
- $a exprese genu $7 D015870
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hydroxyprostaglandindehydrogenasy $x metabolismus $7 D006911
- 650 _2
- $a izoenzymy $x metabolismus $7 D007527
- 650 _2
- $a kinetika $7 D007700
- 650 _2
- $a játra $x enzymologie $7 D008099
- 650 _2
- $a jaterní mikrozomy $x enzymologie $7 D008862
- 650 _2
- $a oxidace-redukce $7 D010084
- 650 _2
- $a rekombinantní proteiny $x metabolismus $7 D011994
- 650 _2
- $a stereoizomerie $7 D013237
- 650 _2
- $a warfarin $x metabolismus $7 D014859
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Sokolová, Simona $u Department of Biochemical Sciences, Faculty of Pharmacy, Charles University, Heyrovského 1203, CZ-50005 Hradec Králové, Czech Republic. Electronic address: simonka.s@centrum.sk.
- 700 1_
- $a Chocholoušová Havlíková, Lucie $u Department of Analytical Chemistry, Faculty of Pharmacy, Charles University, Heyrovského 1203, CZ-50005 Hradec Králové, Czech Republic. Electronic address: havlikova@faf.cuni.cz.
- 700 1_
- $a Wsól, Vladimír $u Department of Biochemical Sciences, Faculty of Pharmacy, Charles University, Heyrovského 1203, CZ-50005 Hradec Králové, Czech Republic. Electronic address: vladimir.wsol@faf.cuni.cz.
- 773 0_
- $w MED00000704 $t Biochemical pharmacology $x 1873-2968 $g Roč. 109, č. - (2016), s. 83-90
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27055738 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170720 $b ABA008
- 991 __
- $a 20170829111536 $b ABA008
- 999 __
- $a ok $b bmc $g 1239763 $s 984995
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 109 $c - $d 83-90 $e 20160404 $i 1873-2968 $m Biochemical pharmacology $n Biochem Pharmacol $x MED00000704
- LZP __
- $a Pubmed-20170720
